---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-002872"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:26:40.231819+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis reports FY2024 revenue ~$84.6M (+15% YoY), above guidance; cash ~$185M

## Summary
- Full year 2024 revenue of ~$84.6M, up 15% from $73.5M in 2023, above guidance range of $83-84M.
- Pharma/enterprise/other revenue grew 20% to ~$77.2M despite Natera revenue declining 20% to ~$25.4M.
- Q4 revenue of ~$16.8M (down 15% YoY); delivered 1,441 molecular tests, up 52% from Q3.
- Cash, cash equivalents, and short-term investments of ~$185.0M, including $50M strategic investment from Merck; path to cash flow break-even.

## SEC filing metadata
- accession: 0001193125-25-002872
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312525002872/0001193125-25-002872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312525002872/d900005d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-002872
- JSON: https://secwatch.observer/filing/0001193125-25-002872.json
- Plain text: https://secwatch.observer/filing/0001193125-25-002872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.